发布求助
文献互助 智能选刊 最新文献

Personalized medicine最新文献

筛选
英文 中文
The use of molecular biomarker tests: an interview study with healthcare providers about a molecular biomarker test for prostate cancer. 分子生物标志物测试的使用:一项关于前列腺癌分子生物标志物测试的医疗服务提供者访谈研究。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-06 DOI: 10.2217/pme-2020-0156
Karine Wendrich, Lotte Krabbenborg
{"title":"The use of molecular biomarker tests: an interview study with healthcare providers about a molecular biomarker test for prostate cancer.","authors":"Karine Wendrich,&nbsp;Lotte Krabbenborg","doi":"10.2217/pme-2020-0156","DOIUrl":"https://doi.org/10.2217/pme-2020-0156","url":null,"abstract":"<p><p><b>Aim:</b> Investigate why healthcare providers are not always willing to use molecular biomarker tests, even though they promise to personalize disease diagnosis and treatment. <b>Materials & methods:</b> We interviewed 20 Dutch urological healthcare providers to ascertain why they used or did not use SelectMDx, a biomarker test for prostate cancer. <b>Results:</b> Whether and how it was used differed from the developers' expectations, because users and nonusers disagreed about its perceived advantages; the scientific and clinical evidence; the advantages of MRI; and the value of <i>PCA3</i> testing. Financial issues and the absence of SelectMDx in professional guidelines and hospital care pathways also hampered its use. <b>Conclusion:</b> Eliciting users' and nonusers' views is important to better understand how biomarker tests can be embedded in clinical practice.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"471-482"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39279620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities. 组学技术在心血管疾病个性化联合治疗中的应用:挑战与机遇。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-25 DOI: 10.2217/pme-2021-0087
Saradindu Banerjee, Navya Prabhu Basrur, Padmalatha S Rai
{"title":"Omics technologies in personalized combination therapy for cardiovascular diseases: challenges and opportunities.","authors":"Saradindu Banerjee,&nbsp;Navya Prabhu Basrur,&nbsp;Padmalatha S Rai","doi":"10.2217/pme-2021-0087","DOIUrl":"https://doi.org/10.2217/pme-2021-0087","url":null,"abstract":"<p><p>The primary purpose of 'omics' technologies is to understand the intricacy of genomics, proteomics, metabolomics and other molecular mechanisms to reveal the complex traits of human diseases. The significant use of omics technologies and their applications in medicine gear up the study of the pathogenesis of several disorders. The detection of biomarkers in the early onset of diseases is challenging; still, omics can discover novel molecular mechanisms and biomarkers. In this review, the different types of omics and their technologies are explicated and aimed to provide their emerging applications in cardiovascular precision medicine. These technologies significantly impact optimizing medical treatment for individuals to reach a higher level in precision medicine.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"595-611"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39568785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
The role of metabolomics in personalized medicine for diabetes. 代谢组学在糖尿病个体化治疗中的作用。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-18 DOI: 10.2217/pme-2021-0083
Shamiha Chowdhury, Sultan Mohammed Faheem, Shaik Sarfaraz Nawaz, Khalid Siddiqui
{"title":"The role of metabolomics in personalized medicine for diabetes.","authors":"Shamiha Chowdhury,&nbsp;Sultan Mohammed Faheem,&nbsp;Shaik Sarfaraz Nawaz,&nbsp;Khalid Siddiqui","doi":"10.2217/pme-2021-0083","DOIUrl":"https://doi.org/10.2217/pme-2021-0083","url":null,"abstract":"<p><p>Metabolomics is rapidly evolving omics technology in personalized medicine, it offers a new avenue for identification of multiple novel metabolic mediators of impaired glucose tolerance and dysglycemia. Liquid chromatography-mass spectrometry, gas chromatography-mass spectrometry and nuclear magnetic resonance spectroscopy are most commonly used analytical methods in the field of metabolomics. Recent evidences showed that metabolomic profiles are link to the incidence of diabetes. In this review, an overview of metabolomics studies in diabetes revealed several diabetes-associated metabolites including 1,5-anhydroglycitol, branch chain amino acids, glucose, α-hydroxybutyric acid, 3-hydroundecanoyl-carnitine and phosphatidylcholine that could be potential biomarkers associated with diabetes. These identified metabolites can be used to develop personalized prognostics and diagnostic, and help in diabetes management.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"501-508"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39324221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The integration of personalized medicine into health systems: progress and a path forward. 将个性化医疗纳入卫生系统:进展和前进道路。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-21 DOI: 10.2217/pme-2021-0102
Daryl Pritchard, Peter J Hulick, Christopher J Wells
{"title":"The integration of personalized medicine into health systems: progress and a path forward.","authors":"Daryl Pritchard,&nbsp;Peter J Hulick,&nbsp;Christopher J Wells","doi":"10.2217/pme-2021-0102","DOIUrl":"https://doi.org/10.2217/pme-2021-0102","url":null,"abstract":"<p><p>Tweetable abstract Fueled by technological advancements and the integration efforts of many pioneer health systems, personalized medicine is now being clinically implemented at measurable but incomplete levels system-wide.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"527-531"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39536009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Life, death, genomics and psychiatry's struggle with esoteric disorders. 生命、死亡、基因组学和精神病学与深奥疾病的斗争。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-25 DOI: 10.2217/pme-2021-0020
Jan Dirk Blom, Brian A Sharpless
{"title":"Life, death, genomics and psychiatry's struggle with esoteric disorders.","authors":"Jan Dirk Blom,&nbsp;Brian A Sharpless","doi":"10.2217/pme-2021-0020","DOIUrl":"https://doi.org/10.2217/pme-2021-0020","url":null,"abstract":"","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"417-421"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39341767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
miR-938rs2505901 T>C polymorphism increases Hirschsprung disease risk: a case-control study of Chinese children. miR-938rs2505901 T>C多态性增加先天性巨结肠疾病风险:一项中国儿童病例对照研究
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-11-11 DOI: 10.2217/pme-2021-0001
Jun Zhong, Jiabin Liu, Yi Zheng, Xiaoli Xie, Qiuming He, Wei Zhong, Qiang Wu
{"title":"<i>miR-938</i><i>rs2505901</i> T>C polymorphism increases Hirschsprung disease risk: a case-control study of Chinese children.","authors":"Jun Zhong,&nbsp;Jiabin Liu,&nbsp;Yi Zheng,&nbsp;Xiaoli Xie,&nbsp;Qiuming He,&nbsp;Wei Zhong,&nbsp;Qiang Wu","doi":"10.2217/pme-2021-0001","DOIUrl":"https://doi.org/10.2217/pme-2021-0001","url":null,"abstract":"<p><p><b>Aim:</b> To explore the association between <i>miR-938</i><i>rs2505901</i> T>C polymorphism and Hirschsprung disease (HSCR) risk in Chinese children. <b>Materials & Methods:</b> We conducted a case-control study in a Chinese population with 1381 cases and 1457 controls. The associated correlation strengths were assessed by adjusted odds ratios (AORs) and 95% CIs. <b>Results:</b> The results revealed that the <i>rs2505901</i> TC and <i>rs2505901</i> TC/CC genotype were related to an increased HSCR risk compared to the risk contributed by the <i>rs2505901</i> TT genotype. A stratification analysis showed that the <i>rs2505901</i> TC/CC genotype promoted the progression of HSCR more significantly in patients with the short-segment HSCR subtype. <b>Conclusion:</b> Our study indicated that <i>miR-938</i><i>rs2505901</i> T>C polymorphism is significantly associated with HSCR risk in Chinese children. This result needs to be confirmed with well-designed studies.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"551-558"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39610717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Defining the role of pharmacists in medication-related genetic counseling. 确定药剂师在药物相关遗传咨询中的作用。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-08-17 DOI: 10.2217/pme-2021-0005
Nova A Chart, David F Kisor, Christopher L Farrell
{"title":"Defining the role of pharmacists in medication-related genetic counseling.","authors":"Nova A Chart,&nbsp;David F Kisor,&nbsp;Christopher L Farrell","doi":"10.2217/pme-2021-0005","DOIUrl":"https://doi.org/10.2217/pme-2021-0005","url":null,"abstract":"<p><p>There is little question that precision medicine will eventually be the standard of care in treatment with algorithms designed for therapy selection and is already being used in some specialties such as cystic fibrosis and multiple cancer treatments. Genetic counselors are the heart of the treatment team in relation to counseling regarding genetic risk factors and disease states. A framework for treatment within the interdisciplinary team with more defined roles and areas of specialty will need to be in place as this practice approach expands with new data and treatments. Pharmacists are poised to be of great assistance in this matrix as many of these roles are merely an extension of current tasks and responsibilities of pharmacy practice.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"509-522"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39331150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinician perspectives on communication and implementation challenges in precision oncology. 临床医生对精准肿瘤学中沟通和实施挑战的看法。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-22 DOI: 10.2217/pme-2021-0048
Jada G Hamilton, Smita C Banerjee, Sigrid V Carlsson, Jacqueline Vera, Kathleen A Lynch, Lili Sar-Graycar, Chloé M Martin, Patricia A Parker, Jennifer L Hay
{"title":"Clinician perspectives on communication and implementation challenges in precision oncology.","authors":"Jada G Hamilton,&nbsp;Smita C Banerjee,&nbsp;Sigrid V Carlsson,&nbsp;Jacqueline Vera,&nbsp;Kathleen A Lynch,&nbsp;Lili Sar-Graycar,&nbsp;Chloé M Martin,&nbsp;Patricia A Parker,&nbsp;Jennifer L Hay","doi":"10.2217/pme-2021-0048","DOIUrl":"https://doi.org/10.2217/pme-2021-0048","url":null,"abstract":"<p><p><b>Aim:</b> To describe patient communication challenges encountered by oncology clinicians, which represent a fundamental barrier to implementing precision oncology. <b>Materials & methods:</b> We conducted three focus groups including breast, melanoma and thoracic oncology clinicians regarding their precision oncology communication experiences. Transcripts were reviewed and coded using inductive thematic text analysis. <b>Results:</b> We identified four themes: varied definitions of precision oncology exist, clinicians and patients face unique challenges to precision oncology implementation, patient communication challenges engendered or heightened by precision oncology implementation and clinician communication solutions and training needs. <b>Conclusion:</b> This study elucidated clinicians' perspectives on implementing precision oncology and related communication challenges. Understanding these challenges and developing strategies to help clinicians navigate these discussions are critical for ensuring that patients reap the full benefits of precision oncology.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"559-572"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607478/pdf/pme-18-559.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39540497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives. 中欧个体化医疗科技合作:综述、趋势和未来展望。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-06-01 DOI: 10.2217/pme-2021-0030
Ilaria Romagnuolo, Claudia Mariut, Andrea Mazzoni, Giovanni de Santis, Ejner Moltzen, Wolfgang Ballensiefen, Carolin Lange, Andrea Frosini, Gianni D'Errico
{"title":"Sino-European science and technology collaboration on personalized medicine: overview, trends and future perspectives.","authors":"Ilaria Romagnuolo,&nbsp;Claudia Mariut,&nbsp;Andrea Mazzoni,&nbsp;Giovanni de Santis,&nbsp;Ejner Moltzen,&nbsp;Wolfgang Ballensiefen,&nbsp;Carolin Lange,&nbsp;Andrea Frosini,&nbsp;Gianni D'Errico","doi":"10.2217/pme-2021-0030","DOIUrl":"https://doi.org/10.2217/pme-2021-0030","url":null,"abstract":"<p><p><b>Aim:</b> Personalized medicine (PM) is revolutionizing biomedical and clinical research while improving the ways healthcare is delivered. The EU is at the forefront of science and innovation in this field, increasing collaborations worldwide. This paper aims to assess the status of recent collaborations between Europe and China in PM-related science, technology and funded research. <b>Methods:</b> We analyze scientific literature, patents and funding programs, respectively. <b>Results:</b> PM is a scientific and industrial priority in both geographical areas, but current levels of collaboration are suboptimal. To increase these levels, policy makers should promote cooperation between researchers, innovators, industries, regulators, funding agencies and healthcare systems, while providing a forum to exchange best practices, define common guidelines for PM implementation and promote public-private partnerships.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 5","pages":"455-470"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39038040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. 胰管腺癌的个体化治疗方法及其在外科实践中的应用。
IF 2.3 4区 医学
Personalized medicine Pub Date : 2021-09-01 Epub Date: 2021-10-22 DOI: 10.2217/pme-2021-0031
Dimitrios Schizas, Alkmini Koumpoura, Meropi Galari, Panagiota Economopoulou, Michail Vailas, Maria Sotiropoulou, Dimitrios Dimitroulis, Ioannis Maroulis, Evangelos Felekouras
{"title":"A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice.","authors":"Dimitrios Schizas,&nbsp;Alkmini Koumpoura,&nbsp;Meropi Galari,&nbsp;Panagiota Economopoulou,&nbsp;Michail Vailas,&nbsp;Maria Sotiropoulou,&nbsp;Dimitrios Dimitroulis,&nbsp;Ioannis Maroulis,&nbsp;Evangelos Felekouras","doi":"10.2217/pme-2021-0031","DOIUrl":"https://doi.org/10.2217/pme-2021-0031","url":null,"abstract":"<p><p>Pancreatic duct adenocarcinoma is an aggressive tumor which constitutes the fourth leading cause of cancer-related mortality in the USA. Despite the fact that surgery is an integral part of treatment, 5-year survival rates remain unfavorable, partly because of the complex genetic background, delayed diagnosis and also the absence of effective therapeutic approaches. To optimize surgery's results in recent years, the use of patients' genetic profile has been implemented through classification into subtypes; subtypes based on mutations which could efficiently lead oncologists to the path of targeted novel neoadjuvant regimens. This approach aims to achieve the most effective selection of patients undergoing surgery, to increase the number of potentially resectable tumors and also control micro-metastases, aiming to extend overall survival.</p>","PeriodicalId":19753,"journal":{"name":"Personalized medicine","volume":"18 6","pages":"613-627"},"PeriodicalIF":2.3,"publicationDate":"2021-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39565305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信